{"nctId":"NCT01428661","briefTitle":"Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder","startDateStruct":{"date":"2011-09"},"conditions":["Major Depressive Disorder"],"count":507,"armGroups":[{"label":"tasimelteon","type":"EXPERIMENTAL","interventionNames":["Drug: tasimelteon"]},{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"tasimelteon","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with diagnosis of MDD, single or recurrent episode, according to DSM-IV TR criteria;\n* Current episode ≥4 weeks and ≤1 year;\n* CGI-Severity score ≥4 at screening and baseline.\n\nExclusion Criteria:\n\n* Lifetime history of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating disorder, or obsessive-compulsive disorder;\n* Any other current Axis I (except general anxiety disorder as long as it is not considered the primary disorder) or Axis II disorder;\n* A positive test for drugs of abuse at the screening visit and/or history of drug or alcohol abuse/dependence as defined in DSM-IV TR, Diagnostic Criteria for Drug and Alcohol Abuse and Dependence, within the past 12 months;\n* Formal psychotherapy within 3 months of the screening visit. General supportive psychotherapy is acceptable;\n* Participation in a previous tasimelteon trial. Other protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D)","description":"Hamilton Rating Scale for Depression (HAM-D) assesses the range of symptoms that are most frequently observed in subjects with major depressive disorder (MDD) on a scale from 0 to 52. Higher HAM-D scores indicate more severe levels of depressive symptoms, thus, a negative change from baseline indicates a reduction (or improvement) in depressive symptoms.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.19","spread":"0.45"},{"groupId":"OG001","value":"-7.83","spread":"0.45"},{"groupId":"OG002","value":"-13.6","spread":"0.34"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":254},"commonTop":["Headache","Nasopharyngitis","Upper Respitory Tract Infection","Somnolence","Diarrhoea"]}}}